Treatment of Pneumocystis carinii pneumonia.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D003622:Dapsone / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D010419:Pentamidine / Q000009:adverse effects / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy* / Q000209:etiology; D011799:Quinazolines / Q000627:therapeutic use; D012008:Recurrence; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016597:Trimetrexate
D004338:Drug Combinations; D005493:Folic Acid Antagonists; D011799:Quinazolines; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D014295:Trimethoprim; D013420:Sulfamethoxazole; D016597:Trimetrexate; D008775:Methylprednisolone